Neuroscience Reaches A New Inflection Point, Big Biotechs Say

Celgene and Biogen are investing in the challenging therapeutic area, fueled by advances in science, growing understanding of the role inflammation may play in neurodegenerative diseases and improved tools for measuring efficacy.

High quality 3d render of nerve cells, concept for Neurologic Diseases, tumors and brain surgery.

A new day is dawning for neuroscience, at least according to some big biotechs, who are investing aggressively in the challenging therapeutic area despite investor reservations. Biogen Inc. took on neuroscience as a core research area several years ago, and it appears the company is as committed to the space as ever under Exec VP-R&D Michael Ehlers, an experienced neuroscientist who took over the role in April. Now Celgene Corp. also has its eye on building a new neuroinflammation franchise.

Ehlers, Celgene CEO Mark Alles and others talked at the J.P. Morgan Healthcare Conference in San Francisco Jan. 9-12 about...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.

Insmed’s New R&D Site Focused On ‘Synthetic Rescue’

 

A new small-molecule approach to turning on beneficial genes to counteract disease-causing mutations is being pioneered by Insmed’s UK-based scientists.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By 

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.

More from Therapy Areas

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By 

The Austrian firm is delisting from the NASDAQ and closing down.

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By 

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

 

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.